Based on the structure of phlorizin, other synthetic SGLT2 inhibitors (SGLT2i) have been developed in the last decade as therapeutic agents to treat type-2 diabetes mellitus (T2DM), which have also been proved to have beneficial effects beyond glucose lowering [9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.